US FDA issued a letter to health-care providers Feb. 9 warning of risks posed by a intragastric balloons used to treat obesity.
The agency says it’s received multiple reports of two kinds of adverse events tied to the use of fluid-filled intragastric balloons used to treat obesity. In the first type of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?